# Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

> **NCT02299765** · PHASE4 · TERMINATED · sponsor: **Sichuan University** · enrollment: 61 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic
- EGFR Activating Mutation

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** gemcitabine
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT02299765
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** the research data is not statistically significant
- **Last updated:** 2017-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02299765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02299765, "Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02299765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*